Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

C4 Therapeutics, Inc. - Common Stock (NQ:CCCC)

3.185 -0.185 (-5.49%)
Delayed Quote Updated: 2:16 PM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about C4 Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
C4 Therapeutics Announces Chief Financial Officer Succession
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Inc. (NASDAQ: CCCC) Highlighted for Surprising Price Action
Via Investor Brand Network
News headline image
The Latest Analyst Ratings for C4 Therapeutics ↗
 
Via Benzinga
News headline image
Looking Into C4 Therapeutics's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Expert Ratings for C4 Therapeutics ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Nasdaq Edges Lower Following Fed Minutes; C4 Therapeutics Shares Jump ↗
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones dropping around 100 points on Wednesday. The Dow traded down 0.30% to 34,316.70 while the NASDAQ fell 0.04% to 13,811.43.... 
Via Benzinga
News headline image
Crude Oil Rises Sharply; Impel Pharmaceuticals Shares Spike Higher ↗
U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 50 points on Wednesday. The Dow traded down 0.17% to 34,361.31 while the NASDAQ fell 0.14% to 13,797.72. The S&P 500,... 
Via Benzinga
C4 Therapeutics Inc. (NASDAQ: CCCC) is One of Wednesday Morning’s Most Active Stocks
Via Investor Brand Network
News headline image
Dow Drops 150 Points; US Factory Orders Increase 0.3% In May ↗
U.S. stocks traded lower this morning, with the Dow Jones dropping over 150 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.46% to 34,259.45 while the NASDAQ fell... 
Via Benzinga
News headline image
Recap: C4 Therapeutics Q1 Earnings ↗
 
Via Benzinga
News headline image
Where C4 Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Looking Into C4 Therapeutics's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
C4 Therapeutics Stock Is Surging: What's Going On? ↗
C4 Therapeutics Inc (NASDAQ: CCCC) shares are rising Wednesday after the clinical-stage biopharmaceutical company announced the FDA cleared its investigational new drug (IND) 
Via Benzinga
News headline image
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
Week In Review: Betta Pharma Enters $392 Million Deal For C4 Therapeutics’ NSCLC Drug ↗
Hangzhou Betta Pharma acquired greater China rights for a novel non-small cell lung cancer drug from Boston’s C4 Therapeutics in a deal worth up to $392 million. Additionally, Lynk Pharma of Hangzhou... 
Via Talk Markets
News headline image
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
News headline image
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Fulcrum Therapeutics Shares Are Trading Lower By Over 55%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Bridger Aerospace Group Holdings, Inc. (NASDAQ: BAER) shares jumped 129.6% to $10.15. Jeffrey E. Kelter reported a 22.4% stake in a 13D filing on Thursday. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2023 ↗
 
Via Benzinga
News headline image
C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics to Present at Two Virtual February 2023 Conferences
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
Ford, Atlassian, Amazon And Other Big Stocks Moving Lower On Friday ↗
U.S. stocks traded lower, with the Dow Jones dropping over 100 points on Friday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.